Last reviewed · How we verify
Iopromide (Ultravist)
Iopromide is a non-ionic, low-osmolarity iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.
Iopromide is a non-ionic, low-osmolarity iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement in angiography and vascular imaging, Contrast enhancement in computed tomography (CT) imaging, Contrast enhancement in urography and other radiographic procedures.
At a glance
| Generic name | Iopromide (Ultravist) |
|---|---|
| Also known as | Ultravist |
| Sponsor | Chinese PLA General Hospital |
| Drug class | Non-ionic iodinated contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iopromide contains iodine atoms that absorb X-rays more effectively than surrounding soft tissues, creating contrast in radiographic images. As a non-ionic contrast agent, it has lower osmolarity than ionic agents, which reduces the risk of adverse reactions and renal toxicity. It is used intravenously to opacify vascular structures and organs during diagnostic imaging.
Approved indications
- Contrast enhancement in angiography and vascular imaging
- Contrast enhancement in computed tomography (CT) imaging
- Contrast enhancement in urography and other radiographic procedures
Common side effects
- Contrast-induced nephropathy
- Allergic reactions (mild to severe)
- Nausea and vomiting
- Flushing and warmth sensation
- Hypersensitivity reactions
Key clinical trials
- Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
- Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging (NA)
- Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions (NA)
- A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
- Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Mammography (NA)
- Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention (NA)
- Serum Thyroid Function After Iodinated Contrast Administration
- Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iopromide (Ultravist) CI brief — competitive landscape report
- Iopromide (Ultravist) updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI